Early Experience of Treprostinil Dry‐Powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Tertiary Referral Center

Key Points

• The aim is to share real-world experiences with the use of treprostinil dry powder inhaler in patients with pulmonary hypertension related to fibrosing interstitial lung disease.
• Described single-center experience
• Used treprostinil dry powder inhaler in patients
• Monitored patient responses in first year
• Documented effectiveness of treprostinil DPI
• Noted patient tolerability
• Potential improvement in quality of life observed